TITLE

Poster 424 Neurodegeneration with Brain Iron Accumulation Type 1 (NBIA‐1): A Case Report

AUTHOR(S)
Kurra, Anupama; Kathirithamby, Rani C.
PUB. DATE
October 2012
SOURCE
PM & R: Journal of Injury, Function & Rehabilitation;Oct2012 Supplement 10S, Vol. 4, pS335
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
No abstract available.
ACCESSION #
133072782

 

Related Articles

  • Pulvinar Sign in Wernicke's Encephalopathy.  // CNS Spectrums: The International Journal of Neuropsychiatric Med;Apr2010, Vol. 15 Issue 4, p215 

    The article discusses the case of a 39-year-old woman who was presented to the German Creutzfeldt-Jacob-Disease (CJD) Surveillance Unit and underwent a tonsillectomy for recurrent infections. Her magnetic resonance image (MRI) showed pulvinar sign in Wernicke's encephalopathy. The case...

  • Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3. Menzies, Fiona M.; Huebener, Jeannette; Renna, Maurizio; Bonin, Michael; Riess, Olaf; Rubinsztein, David C. // Brain: A Journal of Neurology;Jan2010, Vol. 133 Issue 1, p93 

    Spinocerebellar ataxia type 3 is a neurodegenerative disorder caused by the expansion of the polyglutamine repeat region within the ataxin-3 protein. The mutant protein forms intracellular aggregates in the brain. However, the cellular mechanisms causing toxicity are still poorly understood and...

  • Neurotoxicant-induced animal models of Parkinson’s disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Uversky, Vladimir // Cell & Tissue Research;Oct2004, Vol. 318 Issue 1, p225 

    The etiologic basis of Parkinson’s disease (PD), the second most common age-related neurodegenerative disorder, is unknown. Recent epidemiological and experimental studies indicate that exposure to environmental agents, including a number of agricultural chemicals, may contribute to the...

  • Lifespan and mitochondrial control of neurodegeneration. Wright, Alan F.; Jacobson, Samuel G.; Cideciyan, Artur V.; Roman, Alejandro J; Shu, Xinhua; Vlachantoni, Dafni; McInnes, Roderick R.; Riemersma, Rudolph A. // Nature Genetics;Nov2004, Vol. 36 Issue 11, p1153 

    We examine the allometric (comparative scaling) relationships between rates of neurodegeneration resulting from equivalent mutations in a diverse group of genes from five mammalian species with different maximum lifespan potentials. In both retina and brain, rates of neurodegeneration vary by as...

  • ALPERS' DISEASE. Tatum IV, William O.; Kaplan, Peter W.; Jallon, Pierre // Epilepsy A to Z: A Concise Encyclopedia;2009, p14 

    An encyclopedia entry for "Alpers' disease" is presented. It offers clinical information on Alpers' disease in relation to epilepsy. Alpers' disease refers to a syndrome that reflects a genetically determined disorder with rapidly progressive encephalopathy and intractable seizures associated...

  • Las Vegas chamber hosts benefactor of brain institute. Golmassian, Sabrina // Las Vegas Business Press (10712186);5/26/2008, Vol. 25 Issue 21, pP13 

    The article focuses on an address given by Larry Ruvo, senior director at Southern Nevada Wine and Spirits and founder of the Keep Memory Alive Foundation, during the business luncheon of the Las Vegas Chamber of Commerce on May 15, 2008 about the expected impact of the Lou Ruvo Brain Institute...

  • Clinical: Clinical Review - Parkinson's disease. Simpson, Benjamin; Williams, Adrian // GP: General Practitioner;3/5/2010, p43 

    The article presents information related to the parkinson's disease (PD). It is stated that PD occurs due to the progressive loss of dopaminergic neurons in the substantia nigra of the brainstem and is one of the most common neurodegenerative diseases. It is mentioned that the result of an...

  • Alzheimer Disease. Cummings, Jeffrey L.; Cole, Greg // JAMA: Journal of the American Medical Association;5/8/2002, Vol. 287 Issue 18, p2335 

    Focuses on alzheimer disease, a progressive neurodegenerative disorder. Incidence, prevalence, and economic impact; Clinical diagnosis; Pathology; Molecular genetics and pathogenesis; Treatments, including cholinesterase inhibitors.

  • Glyceraldehyde-3-phosphate dehydrogenase as a target for small-molecule disease-modifying therapies in human neurodegenerative disorders. Berry, Mark D. // Journal of Psychiatry & Neuroscience;Sep2004, Vol. 29 Issue 5, p337 

    Recent articles have highlighted numerous additional functions of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) that are independent of its well-documented glycolytic function. One of the most intriguing of these functions is as an initiator of programmed cell death cascades. This activity...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics